FI20002540L - Menetelmä D-vitamiiniyhdisteiden 1alfa-OH-ryhmän lukitsemiseksi aksiaaliseen orientaatioon - Google Patents

Menetelmä D-vitamiiniyhdisteiden 1alfa-OH-ryhmän lukitsemiseksi aksiaaliseen orientaatioon Download PDF

Info

Publication number
FI20002540L
FI20002540L FI20002540A FI20002540A FI20002540L FI 20002540 L FI20002540 L FI 20002540L FI 20002540 A FI20002540 A FI 20002540A FI 20002540 A FI20002540 A FI 20002540A FI 20002540 L FI20002540 L FI 20002540L
Authority
FI
Finland
Prior art keywords
1alpha
vitamin
locking
compounds
group
Prior art date
Application number
FI20002540A
Other languages
English (en)
Swedish (sv)
Other versions
FI20002540A7 (fi
Inventor
Hector F Deluca
Rafal R Sicinski
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of FI20002540L publication Critical patent/FI20002540L/fi
Publication of FI20002540A7 publication Critical patent/FI20002540A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI20002540A 1998-05-21 2000-11-20 Menetelmä D-vitamiiniyhdisteiden 1alfa-OH-ryhmän lukitsemiseksi aksiaaliseen orientaatioon FI20002540A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/082,776 US6114317A (en) 1998-05-21 1998-05-21 Method of locking 1α-OH of vitamin D compounds in axial orientation
PCT/US1999/005204 WO1999059966A1 (en) 1998-05-21 1999-03-10 METHOD OF LOCKING 1α-OH OF VITAMIN D COMPOUNDS IN AXIAL ORIENTATION

Publications (2)

Publication Number Publication Date
FI20002540L true FI20002540L (fi) 2001-01-04
FI20002540A7 FI20002540A7 (fi) 2001-01-04

Family

ID=22173397

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20002540A FI20002540A7 (fi) 1998-05-21 2000-11-20 Menetelmä D-vitamiiniyhdisteiden 1alfa-OH-ryhmän lukitsemiseksi aksiaaliseen orientaatioon

Country Status (10)

Country Link
US (9) US6114317A (fi)
EP (1) EP1077937A1 (fi)
JP (1) JP2002515481A (fi)
KR (1) KR100623127B1 (fi)
CN (1) CN1308609A (fi)
AU (1) AU768724B2 (fi)
CA (1) CA2333103A1 (fi)
FI (1) FI20002540A7 (fi)
NZ (1) NZ508717A (fi)
WO (1) WO1999059966A1 (fi)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
WO1999049870A1 (en) * 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
US6114317A (en) * 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
EP1301479A2 (en) * 2000-07-18 2003-04-16 Bone Care International, Inc. STABILIZED 1$g(a)-HYDROXY VITAMIN D
US20040258801A1 (en) * 2001-09-27 2004-12-23 Alvin Ling Vitamin fortification of foodstuffs
SI1459065T1 (sl) * 2001-12-04 2010-11-30 Teva Pharma Postopki za merjenje potentnosti glatiramer acetata
EP1603530A1 (en) * 2003-03-04 2005-12-14 Teva Pharmaceutical Industries Limited Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
WO2004110380A2 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
US20050031699A1 (en) 2003-06-26 2005-02-10 L'oreal Porous particles loaded with cosmetically or pharmaceutically active compounds
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
US20050009792A1 (en) * 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
EP1796680A2 (en) * 2004-09-14 2007-06-20 Teva Pharmaceutical Industries Ltd Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds
US9338083B2 (en) * 2007-12-28 2016-05-10 At&T Intellectual Property I, Lp ECMP path tracing in an MPLS enabled network
EA201691980A1 (ru) 2009-01-27 2017-07-31 БЕРГ ЭлЭлСи Способы уменьшения побочных эффектов, связанных с химиотерапией
CN102655869B (zh) 2009-08-14 2016-08-10 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
WO2011041596A2 (en) * 2009-10-02 2011-04-07 Wisconsin Alumni Research Foundation 19-nor-vitamin d analogs with 1,2-or 3,2-cyclopentene ring
CA2793727C (en) * 2010-03-23 2017-01-03 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1.alpha.,25-dihydroxyvitamin d3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
US8604009B2 (en) * 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
US9141831B2 (en) 2010-07-08 2015-09-22 Texas Instruments Incorporated Scheduler, security context cache, packet processor, and authentication, encryption modules
CA2851283C (en) * 2011-10-21 2020-07-14 Wisconsin Alumni Research Foundation 2-methylene-vitamin d analogs and their uses
WO2014194133A1 (en) 2013-05-29 2014-12-04 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d
CA2991260A1 (en) * 2015-08-05 2017-02-09 Wisconsin Alumni Research Foundation Synthesis and biological activity of 2-methylene analogs of calcitriol and related compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
NZ232734A (en) * 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
AU650751B2 (en) * 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
JP3213092B2 (ja) * 1991-11-01 2001-09-25 中外製薬株式会社 ２β位に置換基を有するビタミンＤ誘導体
EP0619306B1 (en) * 1993-04-05 1996-09-11 Wisconsin Alumni Research Foundation 19-Nor-vitamin D3 compounds with substituent at 2-position
WO1996001811A1 (en) * 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives
US5877168A (en) * 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6114317A (en) * 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
US20030059749A1 (en) * 2001-09-26 2003-03-27 Keller Mary M. Method for training advisors to students in highly mobile populations

Also Published As

Publication number Publication date
EP1077937A1 (en) 2001-02-28
US7056904B2 (en) 2006-06-06
US20010025036A1 (en) 2001-09-27
WO1999059966A1 (en) 1999-11-25
NZ508717A (en) 2004-01-30
US20050164995A1 (en) 2005-07-28
US6506912B2 (en) 2003-01-14
FI20002540A7 (fi) 2001-01-04
US7094776B2 (en) 2006-08-22
US20030040508A1 (en) 2003-02-27
US6369099B1 (en) 2002-04-09
JP2002515481A (ja) 2002-05-28
AU3075499A (en) 1999-12-06
US6458827B2 (en) 2002-10-01
AU768724B2 (en) 2004-01-08
CA2333103A1 (en) 1999-11-25
US20020068723A1 (en) 2002-06-06
US6482812B2 (en) 2002-11-19
KR100623127B1 (ko) 2006-09-12
US7071179B2 (en) 2006-07-04
CN1308609A (zh) 2001-08-15
US20050182034A1 (en) 2005-08-18
US20020006917A1 (en) 2002-01-17
US6114317A (en) 2000-09-05
US20050182035A1 (en) 2005-08-18
KR20010043737A (ko) 2001-05-25
US6890914B2 (en) 2005-05-10

Similar Documents

Publication Publication Date Title
FI20002540L (fi) Menetelmä D-vitamiiniyhdisteiden 1alfa-OH-ryhmän lukitsemiseksi aksiaaliseen orientaatioon
EE04277B1 (et) Taksoidide klassi kuuluvate derivaatide valmistamismeetod
DE19983812T1 (de) Verriegelungsspannfutter
FI965268A0 (fi) Menetelmä moniarvoisten alkoholien valmistamiseksi
IT1315269B1 (it) Metodo per la preparazione di 5-cianoftalide
AT501583B1 (de) Dualband-antenne und verfahren zu ihrer herstellung
PT1105382E (pt) Metodo para a preparacao de citalopran
PT916675E (pt) Processo para preparacao de sildenafil
ATE274491T1 (de) Phenylglycin-derivate
DE69820853D1 (de) Axiallüfter
IT1317741B1 (it) Metodo per la preparazione di 5-cianoftalide.
FI960818L (fi) Menetelmä aromaattisten nitroyhdisteiden pelkistämiseksi
IT1319251B1 (it) Metodo per la preparazione di 5-carbossiftalide.
ATA193297A (de) Präzisionswalzverfahren
PT1028960E (pt) Processo para a preparacao de derivados de tiazolidinodiona
DE69801795D1 (de) Indolyl-pyrrolylidenmethylpyrrol-derivate und verfahren zu ihrer herstellung
NO995851D0 (no) Fremstillingsfremgangsmåte for isoksasolidinedion forbindelse
DE69729696D1 (de) Axial-Verriegelung
NO20003454D0 (no) FremgangsmÕte for fremstilling av (-)cis-3-hydroksy-1-metyl-4-
TR199800403A3 (tr) a-Bromo-laktam türevlerinin hazirlanmasi için yöntem.
EE200200014A (et) Dibensotiasepiiniderivaatide valmistamismeetod
DE69932578T8 (de) Trifluoro-methylthiomethyl-benzolderivate und verfahren zu ihrer herstellung
GB9805999D0 (en) Method for the preparation of emulsions
BR9709511A (pt) Processo para a preparacão de arilpirazóis substituídos
EE9900404A (et) Arüülaminotriasolopüridiinide valmistamise meetod

Legal Events

Date Code Title Description
MA Patent expired